EGFR and non-small cell lung carcinoma: Erlotinib, one of the first-generation EGFR-TKIs35–37 binds competitively and reversibly to the ATP-binding site of the EGFR TK domain, and shows a significant advance treatment in selected NSCLC patients with activating EGFR mutations.